Justin Irizarry, CEO
South Miami, FL
OrganaBio democratizes access to critical, hard to procure resources to advance the clinical translation and commercialization of cell-based therapies. OrganaBio currently produces MSCs, NK, and T-cells from its proprietary supply chain of perinatal tissue and will soon offer adult peripheral blood mononuclear cells. OrganaBio’s products are supported by a robust QC, QA, and regulatory documentation package. OrganaBio partners can source GMP cells and manufacture their products in its novel multi-tenant cGMP facility, with access to the Quality and Manufacturing systems needed to do so. In addition, partners can leverage a host of services (process development, QA, QC, analytical testing and regulatory affairs support), eliminating the need to coordinate multiple vendors and service providers, and maintaining control over their process and product. OrganaBio’s unique end-to-end industry solution, positioned at the intersection of several critical resources, spurs rapid development of cell-based therapies, ultimately benefiting patients.

By using this website you agree to accept our Privacy Policy and Terms & Conditions